NanoStrike Research

The Defend 1050 achieved a 4.53 log10 reduction of live SARS-CoV-2 virus, which equates to a 99.997% percentage reduction, in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.

The Defend 1050 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.99% in 15 minutes at Aerosol Research and Engineering Laboratories in Kansas.

The Defend 400 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.9995% in 45 minutes at Aerosol Research and Engineering Laboratories in Kansas.

The Protect 200 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.991% in 180 minutes at Aerosol Research and Engineering Laboratories in Kansas.

Novaerus NV950 (Protect 900) cleaned 100% of the air in a room of 22.65m³ (800 ft³) in 21-24 minutes, dependent on fan speed at the Cork Institute of Technology in Cork, Ireland.

The Protect 800/900 shown to reduce overall allergens by 41.16%, including house dust mites, feline dander, canine dander, and pollen at Indoor Biotechnologies Ltd. in Cardiff, UK.

The Defend 1050 was shown to reduce aerosolized Aspergillus niger spores at Aerosol Research and Engineering Laboratories in Kansas.

The Defend 1050 showed a 4-log (99.99%) reduction in Bacillus Globigii endospores within 15 minutes, which was maintained over the prolonged operation (24 hours).

The Protect 900 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99.87% reduction), MS2 bacteriophage (99.99% reduction), Aspergillus niger fungus (99.1% reduction), and Bacillus subtilis endospores (86.63% reduction) at Aerosol Research and Engineering Laboratories in Kansas.

The Defend 1050 was shown to reduce 99.6% of airborne C. difficile within the first 20 minutes of operation and >99.9% after 40 minutes at Airmid Health Group Ltd. in Ireland.

The Protect 800/900 was shown to reduce formaldehyde by 85% during a 14-hour testing experiment at Avomeen Analytical Services in Michigan.

The Defend 1050 had an average net LOG reduction of 2.52 LOG across four tests and formaldehyde levels reached 0.00 ppm in an average of 1.1 minutes at Aerosol Research and Engineering Laboratories in Kansas.

The Defend 1050 was shown to reduce 99.9% of airborne Influenza A within the first 10-20 minutes of operation at the Airmid Health Group Ltd. in Ireland.

The Protect 200 effective at removing 51.8% of the Influenza H1N1 virus from the air after 1 passage (or 44 seconds) through the device.

The Defend 1050 was able to reduce the concentration of human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for Measles virus, by 99.87% after 25 minutes at the Airmid Healthgroup in Ireland.

The Protect 200 rendered all airborne Mycobacterium tuberculosis non-viable at Qualilife Diagnostics in India.

The Defend 1050 was shown to reduce the concentration of M. smegmatis (surrogate for M. tuberculosis) by 97% after 30 minutes of operation at Airmid Healthgroup in Ireland.

The Defend 1050 reduced the chamber concentration of Nitrogen Dioxide (NO₂) to 0.0 ppm at 7.5 minutes in all three trials at Aerosol Research and Engineering Laboratories in Kansas.

The Defend 1050 removed 99% of PM2.5 within 6.26 minutes and 99% of PM1.0 within 6.33 minutes at the Camfil Laboratories – Tech Center in Sweden.

The Defend 1050 was shown to reduce phi X 174 virus by 98.8% in 30 minutes at the Korea Testing Laboratory.

The Protect 900 was shown to reduce 99.99% of methicillin-resistant Staphylococcus aureus (MRSA) within 4 hours at Microbac Laboratories, Inc. in North Carolina.

The Defend 1050 was shown to reduce Staphylococcus epidermidis bacteria by 99.9% in 60 minutes at the Korea Testing Laboratory.

The Defend 1050 achieved a microbial cell reduction of 99.94% of Staphylococcus epidermidis within 15 minutes of operation at the Novaerus Research and Development Labs in Ireland.

The Protect 800/900 shown to reduce 95% of Staphylococcus epidermidis aerosol contamination in 30 minutes at the University of Huddersfield in England.

The Defend 1050 achieved 90% VOC removal after 6 - 16 minutes, dependent on fan speed at the Camfil Laboratories – Tech Center in Sweden.

This booklet provides a summary of laboratory and clinical research conducted on the NuvaWave handheld device. Studies include efficacy against Virus and Bacteria including live SARS-CoV-2.

The Defend 400 reduced PM 1 by 99.99% in 26 minutes with an eCADR of 340.7 m³/h. PM 2.5 was reduced by 99.99% in 25.9 minutes with an eCADR of 341.0 m³/h.

The Defend 400 achieved a net LOG reduction of Bacillus Globigii endospores after 45 minutes of 4.55 which is equivalent to a net percent reduction of 99.9969%.

The Defend 400 achieved greater than a log-4 reduction (>99.99%) of Staphylococcus epidermidis after 45 minutes.

WellAir’s solutions help to reduce the microbial load in the air and surfaces and thus hospital-acquired infections. This intervention study was conducted in two similar ICUs between May to November of 2020.

Novaerus reduces VOCs by 93%, airborne bacteria by 87% and molds by 67% at the Fresenius Dialysis Centres in Portugal.

Novaerus shown to reduce airborne Staphylococcus by 100%, airborne bacteria by 89% and airborne fungi by 87% Bucharest Emergency University Hospital in Romania.

Novaerus reduces environmental surface MRSA by 97% and reduces environmental surface TVC and environmental air MRSA at the Royal Free Hospital in London.

Novaerus reduces staff sickness, ward odors, infections and antibiotic use. Wards with Novaerus have had no outbreaks of MRSA, C. diff, influenza, or norovirus since installation at the Leopardstown Park Hospital in Ireland.

Novaerus shown to reduce airborne bacteria and fungi 96% at the “Dr V. Babes” Hospital of Infectious and Tropical Diseases in Romania.

Novaerus plasma technology shown to significantly reduce number of microorganisms at the Brothers Hospitallers of Saint John of God Hospital in Poland.

Novaerus shown to reduce bacterial loads on high surfaces and window sills as well as reduce overall infection rates by 23% compared to increase of infection rates by 35% in control section at Rigshospitalet in Denmark.

Novaerus reduces bacterial colony count in both the rooms that were being used and those that were empty at Ain Shams University in Egypt.

Novaerus devices effectively reduce the number of airborne pathogens by 61% in the admission room of the Pediatric Department and by 19% in the Clinic of Pulmonology/Tuberculosis and Pulmonary Diseases at Międzyrzecz Hospital in Poland.

Novaerus reduces CFU rates by 82% and fungi count by 93% after 2 months of operation at Uzsoki Hospital in Hungary.

The Protect 200 and Protect 900 devices significantly reduce number of microorganisms as well as eliminate unwanted odors at Specialized Hospital in Chorzów, Poland.

This 20-month study compares the total number of respiratory nosocomial infections before and after implementation of the Protect 900 units.

This 35-month study compares the total number of respiratory nosocomial infections and infection rates before and after each implementation of the Protect 900 technology at Canterbury Tower in Florida.

This 24-month study compares the total number of respiratory nosocomial infections before and after implementation of the Protect technology at Edgehill Nursing and Rehabilitation Center (ENRC) in Pennsylvania.

Since 2014, the Haus an der Traisen nursing home in St. Pölten, Austria have supplemented their existing hygiene protocols with Novaerus air purification units to help control infection and reduce odor.

This 24-month study compares the total number of repeat infections, nosocomial C. difficile infections, and nosocomial respiratory infections before and after implementation of the Novaerus technology at Hialeah Nursing and Rehab Center (HNRC) in Florida.

Linde Healthcare, a Vienna-based healthcare company, had no existing healthy air solution in place for its 16 person open floorplan office space. Curious about Novaerus’s innovative technology, they reached out to learn more.

After learning about the safety and efficacy of Novaerus' low-energy plasma technology from a local distributor, and that the products are made with medical-grade materials, Kindergarten Mamos Delne in Lithuania tried the technology in each of their three classrooms.

This 24-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Manchester Manor Health Care Center (MMHCC) in Connecticut.

As COVID-19 rapidly spread across the globe, healthcare facilities around the world had to adapt and prepare for a pandemic. For Masfiv, a newly built medical centre in Spain specializing in reproductive medicine and gynaecological health, this meant maintaining minimal essential reproductive care services while containing the spread of coronavirus. In line with public health guidelines, Masfiv established a range of COVID-19 protocols. One of these protocols; 24/7 air dis-infection technology by Novaerus. 

This 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Meadow View Nursing Center (MVNC) in Pennsylvania.

This 28-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Naamans Creek Country Manor (NCCM) in Pennsylvania.

This 29-month study compares the average monthly rate of nosocomial respiratory infections before and after implementation of the Novaerus technology at Page Rehabilitation and Healthcare Center (PRHC) in Florida.

Patki Hospital, an IVF centre specialized in obstetrics, infertility and gynaecology in India, were looking for a solution to reduce airborne VOC and infection load in their lab. After investigating various options, the hospital decided to deploy a Novaerus Defend 1050. The result; improved outcomes and air quality. 

Sante International has provided solutions to the Romanian healthcare industry since 1992 and has partnered with Novaerus since 2014. Over a 3-month period, they proved Novaerus technology is more efficient and safer with no maintenance and at a low cost.

As part of a trial to measure background pollution and pathogenic organisms, Novaerus units were placed in 4 locations in the University of Szeged’s Department of Geriatrics and Chronic Diseases of the Internal Medicine Clinic No. 1 in Hungary. The medical clinic was interested in improving overall air quality in the geriatric and chronic disease wards.

This 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Vernon Manor Health Care Center (VMHCC) in Connecticut.

This 23-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Village at Manor Park (VMP) in Wisconsin.

Two weeks after installation, staff at Wassan Dental Specialty Centre in Oman observed a noticeable reduction in odor. Staff were reassured to know that Novaerus was operating continuously in the background to eliminate VOC, infectious pathogens and allergens from the air.